Digital TwinApril 2026
Digital Twins Become Strategic Imperative in Pharma: FDA and EMA Back Model-Based Evidence
Multiple publications and industry reports confirm that digital twins in pharma are no longer emerging — they are a strategic imperative in 2026. The FDA and EMA increasingly support model-based evidence. Applications span the entire R&D lifecycle from target discovery to clinical trials.
JFInnova Perspective
JFInnova's pipeline uses ODE-based digital twins and agent-based models to simulate cellular response to MIF/CD74 blockade. With growing regulatory support for model-based evidence, our platform is positioned to generate regulator-accepted data before any clinical trial.
References
1
Digital twins in pharmaceutical development
Drug Discovery Today · 2026
digital twin pharma FDA EMA model-based evidence